Condition: Fuchs · Fuchs Dystrophy · Fuchs' Endothelial Dystrophy · Sponsor: Stanford University
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
This description comes directly from the study's public registry record.
Nicole Varnado, MPH · 650-725-1688 · nvarnado@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford University | Palo Alto, California, United States | Recruiting |
| University of California Davis | Sacramento, California, United States | Recruiting |
| University of Miami | Palm Beach Gardens, Florida, United States | Recruiting |
| Dartmouth-Hitchcock Medical Center | Lebanon, New Hampshire, United States | Recruiting |
| Legacy Devers Eye Institute | Portland, Oregon, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Wills Eye Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05275972